IJCS | Volume 32, Nº2, March/April 2019

188 14. Desai HV, AronowWS, Peterson SJ, FrishmanWH. Cardiac amyloidosis: approaches to diagnosis andmanagement. Cardiol Rev. 2010;18(1):1-11. 15. Narotsky DL, Castano A, Weinsaft JW, Bokhari S, Maurer MS. Wild- type transthyretin cardiac amyloidosis: novel insights from advanced imaging. Can J Cardiol. 2016;32(9):1166.e1-1166.e10. 16. Mesquita ET, Jorge AJ, Souza CV Junior, Andrade TR. Cardiac amyloidosis and its new clinical phenotype: heart failure with preserved ejection fraction. Arq Bras Cardiol. 2017;109(1):71-80. 17. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364. 18. Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol. 2013;38(2):53-96. 19. Rocha AM, Ferreira SG, Nacif MS, Ribeiro ML, Freitas MR, Mesquita CT. Speckle tracking and transthyretin amyloid cardiomyopathy. Arq Bras Cardiol. 2017;108(1):21-30. 20. Patel AR, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol. 1997;80(4):486-92. 21. Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16(2):63-70. 22. Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN. Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica. 2011;96(7):1079-80. 23. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787-9. 24. Hawkins PN, Lavender JP, PepysMB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508-13. 25. deMiguel C, Llorente L, de Haro-Del Moral FJ, Garcia-Pavia P, Gonzalez- Lopez E, Segovia J, et al. Myocardial uptake of (99m)Tc-DPD in patients with AL amyloidosis. Amyloid. 2017;24(supl1):48-9. 26. Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18(12):1344-50. 27. Moore PT, Burrage MK, Mackenzie E, Law WP, Korczyk D, Mollee P. The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience. Heart Lung Circ. 2017;26(11):1183-90. 28. SachchithananthamS, Hutt DF, QuigleyAM, Hawkins P,Wechalekar AD. Role of (99m) Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis. Br J Haematol. 2017 Oct 30. [Epub ahead of print]. 29. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488-97. 30. Bluemke DA, Boxerman JL, Mosher T, Lima JA. Segmented K-space cine breath-hold cardiovascular MR imaging: Part 2. Evaluation of aortic vasculopathy. AJR Am J Roentgenol. 1997;169(2):401-7. 31. Bluemke DA, Boxerman JL, Atalar E, McVeigh ER. Segmented K-space cine breath-hold cardiovascular MR imaging: Part 1. Principles and technique. AJR Am J Roentgenol. 1997;169(2):395-400. 32. Barkhausen J, Ruehm SG, Goyen M, Buck T, Laub G, Debatin JF. MR evaluation of ventricular function: true fast imaging with steady-state precession versus fast low-angle shot cineMR imaging: feasibility study. Radiology. 2001;219(1):264-9. 33. Tyler DJ, Hudsmith LE, Petersen SE, Francis JM, Weale P, Neubauer S, et al. Cardiac cine MR-imaging at 3T: FLASH vs SSFP. J Cardiovasc Magn Reson. 2006;8(5):709-15. 34. Axel L, Dougherty L. MR imaging of motion with spatial modulation of magnetization. Radiology. 1989;171(3):841-5. 35. Biglands JD, Radjenovic A, Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: Part II. J Cardiovasc Magn Reson. 2012 Sep 20;14:66. 36. Zerhouni EA, Parish DM, Rogers WJ, Yang A, Shapiro EP. Human heart: tagging with MR imaging--a method for noninvasive assessment of myocardial motion. Radiology. 1988;169(1):59-63. 37. Kuetting DL, Homsi R, Sprinkart AM, Luetkens J, Thomas DK, Schild HH, et al. Quantitative assessment of systolic and diastolic function in patients with LGE negative systemic amyloidosis using CMR. Int J Cardiol. 2017 Apr 1;232:336-41. 38. Oda S, Utsunomiya D, Nakaura T, Yuki H, Kidoh M, Morita K, et al. Identification and assessment of cardiac amyloidosis by myocardial strain analysis of cardiac magnetic resonance imaging. Circ J. 2017;81(7):1014-21. 39. Diesbourg LD, Prato FS, Wisenberg G, Drost DJ, Marshall TP, Carroll SE, et al. Quantification of myocardial blood flow and extracellular volumes using a bolus injection of Gd-DTPA: kinetic modeling in canine ischemic disease. Magn Reson Med. 1992;23(2):239-53. 40. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94(12):3318-26. 41. Saeed M, Wendland MF, Masui T, Higgins CB. Reperfused myocardial infarctions on T1- and susceptibility-enhanced MRI: evidence for loss of compartmentalizationofcontrastmedia.MagnResonMed.1994;31(1):31-9. 42. Simonetti OP, KimRJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improvedMR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1):215-23. 43. Raina S, Lensing SY, Nairooz RS, Pothineni NV, Hakeem A, Bhatti S, et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. JACC Cardiovasc Imaging. 2016;9(11):1267-77. 44. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, et al. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson. 2012 May 1;14:27. 45. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, et al. T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd- BOPTA. J Cardiovasc Magn Reson. 2012 Apr 28;14:26. 46. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, et al. Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson. 2011 Nov 28;13:75. 47. Liu CY, Liu YC, Wu C, Armstrong A, Volpe GJ, van der Geest RJ, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;62(14):1280-7. 48. Liu S, Han J, Nacif MS, Jones J, Kawel N, Kellman P, et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J Cardiovasc Magn Reson. 2012 Dec 28;14:90. 49. Nacif MS, Raman FS, Gai N, Jones J, van der Geest RJ, T Sibley C, et al. Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium. Radiol Bras. 2018;51(1):13-9. 50. Nacif MS, Turkbey EB, Gai N, Nazarian S, van der Geest RJ, Noureldin RA, et al. Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences. J Magn Reson Imaging. 2011;34(6):1367-73. Ribeiro et al. CMR and amyloidosis Int J Cardiovasc Sci. 2019;32(2)177-189 Review Article